Nuvation Bio (NUVB) Jefferies Global Healthcare Conference 2026 summary

Commercial performance and product differentiation

• IBTROZI leads the ROS1 space with a 90% response rate and 50-month median duration of response, showing strong first-line patient growth of 35% quarter-over-quarter since launch.

• The drug's high efficacy, tolerability, and chronic use profile drive long-term market potential, with patients staying on therapy for extended periods.

• Recent patient-reported outcomes show 88% of patients improved or stable, with unique cognitive benefits and rapid symptom relief.

• IBTROZI's robust CNS coverage and inclusion in NCCN CNS guidelines further differentiate it, especially for preventing brain metastases.

• NCCN guideline changes now require ROS1 agents as first-line therapy, streamlining commercial messaging and expected to boost IBTROZI adoption.

Market dynamics, competition, and growth strategies

• The ROS1 market is evolving toward chronic disease dynamics, with revenue stacking expected from long duration of response.

• Early and increased molecular testing, driven by precision oncology advances and adjuvant studies, is expanding the addressable market.

• Competitive threats from NUV-1511 and NUV-868 are mitigated by IBTROZI's head start, superior efficacy, and real-world data inclusivity.

• The commercial team emphasizes IBTROZI's broad applicability, including patients with concomitant driver mutations, unlike some competitors.

• TRK-B inhibition is positioned as a mechanistic advantage for CNS protection, with low discontinuation rates supporting tolerability.

Pipeline development and clinical trial updates

• Safusidenib targets all four IDH1 mutant glioma subgroups, with ongoing SIGMA and grade III oligo studies; first data readout expected in 2027.

• The glioma market is large due to long patient survival, with tens of thousands of prevalent cases and significant revenue stacking potential.

• Safusidenib shows a 44% response rate in low-grade glioma and durable benefit, with a new post-vorasidenib failure study in design.

• Mechanistically, safusidenib may offer immune-mediated benefits distinct from vorasidenib, supporting its use after prior therapy failure.

• The adjuvant TRUST-IV study for IBTROZI is on track, aiming to expand into earlier-stage disease and further increase market opportunity.